ClinicalTrials.gg
RecruitingNCT06371157Updated Mar 12, 2025

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

A Phase 3 interventional study of AK104 and Lenvatinib in Hepatocellular Carcinoma, sponsored by Akeso. Recruiting at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
469
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cadonilimab in Carcinoma, Hepatocellular — 13 open to participants now, 16 under way, 2 of them phase 3. cadonilimab · Carcinoma, Hepatocellular.

Planned enrollment
2nd of 23
469 · median 36
Started
2024
with 5 others
Phase 3
2 of 23
2 open now
Primary completion
2025-10
later than 6 of 15 live
Registered
19th of 23
by date
Lead sponsor
6 of 23
Akeso

Among the 23 studies testing cadonilimab in Carcinoma, Hepatocellular, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 6 of the 15 other live ones, and was the 19th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

13 of the 23 studies testing cadonilimab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cadonilimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a diagnosis of HCC confirmed by histology/cytology,or meet the clinical diagnostic criteria of the American Association for the Study of Liver Diseases (AASLD)
  2. No evidence of
  3. Not amenable to curative surgery or transplantation or curative ablation but amenable to TACE
  4. score class A
  5. (ECOG) performance status of 0 or 1 at enrollment
  6. by 1.1
  7. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. History of liver transplantation
  2. History of hepatic encephalopathy
  3. Uncontrolled arterial hypertension
  4. Deep venous thrombosis within 3 months before first treatment
  5. Bleeding events within the last 6 months
  6. Co-infection with and
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
469 participants (estimated)

Study arms

  • Experimental
    Arm A

    AK104+ Lenvatinib in Combination With Transarterial Chemoembolization (TACE)

    Drug: AK104 · Drug: Lenvatinib · Procedure: TACE

  • Placebo comparator
    Arm B

    Placebo for AK104 + Placebo for Lenvatinib in Combination With TACE

    Procedure: TACE · Other: Placebo for AK104 · Other: Placebo for Lenvatinib

  • Other
    Arm C

    AK104 + Placebo for Lenvatinib in Combination With TACE

    Drug: AK104 · Procedure: TACE · Other: Placebo for Lenvatinib

Interventions

  • DrugAK104

    intravenous

  • oral

  • ProcedureTACE

    TACE (chemo and embolic agent injection into the hepatic artery)

  • OtherPlacebo for AK104

    intravenous

  • OtherPlacebo for Lenvatinib

    oral

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR).

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 2 years

  2. PFS per RECIST 1.1

    Assessed by investigators

    Time frame: Up to approximately 2 years

  3. Objective Response Rate (ORR) per RECIST 1.1 and Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    Assessed by BICR and investigators

    Time frame: Up to approximately 2 years

  4. Duration of Response (DOR) per RECIST 1.1 and mRECIST

    Assessed by BICR and investigators

    Time frame: Up to approximately 2 years

  5. Disease Control Rate (DCR) per RECIST 1.1 and mRECIST

    Assessed by BICR and investigators

    Time frame: Up to approximately 2 years

  6. Time to Response (TTR) per RECIST 1.1 and mRECIST

    Assessed by BICR and investigators

    Time frame: Up to approximately 2 years

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Oct 2025, 14 months after the start.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's planned 14 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 17, 2024
StartActual
Aug 2, 2024
Primary completionEst.
Oct 25, 2025
CompletionEst.
May 23, 2026
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06371157
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Aug 2, 2024
Primary completion
Oct 25, 2025 (estimated)
Completion
May 23, 2026 (estimated)
Last update
Mar 12, 2025

Study contacts

Ting Liu
Contact
clinicaltrials@akesobio.com
+86 (0760) 8987 3999
Guoliang Shao, MD
principal investigator · Zhejiang Cancer Hospital
Gaojun Teng, MD
principal investigator · Zhongda Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion